

# Graziana Colaianni

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1677687/publications.pdf>

Version: 2024-02-01

87  
papers

3,905  
citations

101535

36  
h-index

133244

59  
g-index

93  
all docs

93  
docs citations

93  
times ranked

4490  
citing authors

#	ARTICLE	IF	CITATIONS
1	The myokine irisin increases cortical bone mass. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 12157-12162.	7.1	372
2	Oxytocin is an anabolic bone hormone. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 7149-7154.	7.1	223
3	Irisin prevents and restores bone loss and muscle atrophy in hind-limb suspended mice. Scientific Reports, 2017, 7, 2811.	3.3	221
4	Irisin Enhances Osteoblast Differentiation <i>In Vitro</i> . International Journal of Endocrinology, 2014, 2014, 1-8.	1.5	161
5	T cells support osteoclastogenesis in an in vitro model derived from human multiple myeloma bone disease: the role of the OPG/TRAIL interaction. Blood, 2004, 104, 3722-3730.	1.4	138
6	Regulation of bone remodeling by vasopressin explains the bone loss in hyponatremia. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 18644-18649.	7.1	120
7	Increased Osteoclast Activity in the Presence of Increased Homocysteine Concentrations. Clinical Chemistry, 2005, 51, 2348-2353.	3.2	113
8	Irisin and musculoskeletal health. Annals of the New York Academy of Sciences, 2017, 1402, 5-9.	3.8	112
9	Microgravity during spaceflight directly affects <i>in vitro</i> osteoclastogenesis and bone resorption. FASEB Journal, 2009, 23, 2549-2554.	0.5	106
10	The role of hyperhomocysteinemia as well as folate, vitamin B6 and B12 deficiencies in osteoporosis â€” a systematic review. Clinical Chemistry and Laboratory Medicine, 2007, 45, 1621-32.	2.3	105
11	High dose M-CSF partially rescues the Dap12 <sup>+/+</sup> osteoclast phenotype. Journal of Cellular Biochemistry, 2003, 90, 871-883.	2.6	94
12	Irisin Prevents Disuse-Induced Osteocyte Apoptosis. Journal of Bone and Mineral Research, 2020, 35, 766-775.	2.8	82
13	Osteogenic differentiation of mesenchymal stem cells from dental bud: Role of integrins and cadherins. Stem Cell Research, 2015, 15, 618-628.	0.7	70
14	High Sclerostin and Dickkopf-1 (DKK-1) Serum Levels in Children and Adolescents With Type 1 Diabetes Mellitus. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 1174-1181.	3.6	67
15	Bone Marrow Oxytocin Mediates the Anabolic Action of Estrogen on the Skeleton. Journal of Biological Chemistry, 2012, 287, 29159-29167.	3.4	66
16	Osteoblast regulation via ligand-activated nuclear trafficking of the oxytocin receptor. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 16502-16507.	7.1	63
17	Thyroid-stimulating hormone induces a Wnt-dependent, feed-forward loop for osteoblastogenesis in embryonic stem cell cultures. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 16277-16282.	7.1	60
18	High irisin levels are associated with better glycemic control and bone health in children with Type 1 diabetes. Diabetes Research and Clinical Practice, 2018, 141, 10-17.	2.8	60

#	ARTICLE	IF	CITATIONS
19	Human osteoclasts express oxytocin receptor. <i>Biochemical and Biophysical Research Communications</i> , 2002, 297, 442-445.	2.1	58
20	Bisphosphonates inactivate human EGFRs to exert antitumor actions. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 17989-17994.	7.1	57
21	Osteoporosis and obesity: Role of Wnt pathway in human and murine models. <i>World Journal of Orthopedics</i> , 2014, 5, 242.	1.8	56
22	Functions of vasopressin and oxytocin in bone mass regulation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 164-169.	7.1	54
23	Stimulation of osteoclast activity by low B-vitamin concentrations. <i>Bone</i> , 2007, 41, 584-591.	2.9	52
24	Repurposing of bisphosphonates for the prevention and therapy of nonsmall cell lung and breast cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 17995-18000.	7.1	52
25	LIGHT/TNFSF14 increases osteoclastogenesis and decreases osteoblastogenesis in multiple myeloma-bone disease. <i>Oncotarget</i> , 2014, 5, 12950-12967.	1.8	52
26	Regulated production of the pituitary hormone oxytocin from murine and human osteoblasts. <i>Biochemical and Biophysical Research Communications</i> , 2011, 411, 512-515.	2.1	47
27	Role of Irisin on the bone-muscle functional unit. <i>BoneKEY Reports</i> , 2015, 4, 765.	2.7	47
28	Vitamin D Effects on Osteoblastic Differentiation of Mesenchymal Stem Cells from Dental Tissues. <i>Stem Cells International</i> , 2016, 2016, 1-9.	2.5	47
29	M-CSF Regulates the Cytoskeleton via Recruitment of a Multimeric Signaling Complex to c-Fms Tyr-559/697/721. <i>Journal of Biological Chemistry</i> , 2007, 282, 18991-18999.	3.4	46
30	Monoclonal antibodies for treating osteoporosis. <i>Expert Opinion on Biological Therapy</i> , 2018, 18, 149-157.	3.1	45
31	Irisin serum levels are positively correlated with bone mineral status in a population of healthy children. <i>Pediatric Research</i> , 2019, 85, 484-488.	2.3	45
32	The Oxytocin-Bone Axis. <i>Journal of Neuroendocrinology</i> , 2014, 26, 53-57.	2.6	43
33	Mechanisms Involved in Childhood Obesity-Related Bone Fragility. <i>Frontiers in Endocrinology</i> , 2019, 10, 269.	3.5	43
34	Irisin Correlates Positively With BMD in a Cohort of Older Adult Patients and Downregulates the Senescent Marker p21 in Osteoblasts. <i>Journal of Bone and Mineral Research</i> , 2020, 36, 305-314.	2.8	42
35	Stimulation of osteoblast activity by homocysteine. <i>Journal of Cellular and Molecular Medicine</i> , 2008, 12, 1205-1210.	3.6	41
36	Oxytocin deficiency impairs maternal skeletal remodeling. <i>Biochemical and Biophysical Research Communications</i> , 2009, 388, 161-166.	2.1	41

#	ARTICLE	IF	CITATIONS
37	High dickkopf-1 levels in sera and leukocytes from children with 21-hydroxylase deficiency on chronic glucocorticoid treatment. American Journal of Physiology - Endocrinology and Metabolism, 2013, 304, E546-E554.	3.5	41
38	A Novel Interplay Between Irisin and PTH: From Basic Studies to Clinical Evidence in Hyperparathyroidism. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 3088-3096.	3.6	41
39	Irisin and Bone: From Preclinical Studies to the Evaluation of Its Circulating Levels in Different Populations of Human Subjects. Cells, 2019, 8, 451.	4.1	41
40	Irisin prevents microgravity-induced impairment of osteoblast differentiation in vitro during the space flight CRS-14 mission. FASEB Journal, 2020, 34, 10096-10106.	0.5	38
41	Oxytocin regulates body composition. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 26808-26815.	7.1	34
42	FSH and TSH in the Regulation of Bone Mass: The Pituitary/Immune/Bone Axis. Clinical and Developmental Immunology, 2013, 2013, 1-6.	3.3	33
43	LIGHT/TNFSF14 Promotes Osteolytic Bone Metastases in Non-small Cell Lung Cancer Patients. Journal of Bone and Mineral Research, 2020, 35, 671-680.	2.8	31
44	An update on the role of RANKL/RANK/osteoprotegerin and WNT- $\beta$ -catenin signaling pathways in pediatric diseases. World Journal of Pediatrics, 2019, 15, 4-11.	1.8	29
45	Vitamin D Promotes MSC Osteogenic Differentiation Stimulating Cell Adhesion and $\beta$ -Casein Expression. Stem Cells International, 2018, 2018, 1-9.	2.5	28
46	Oxytocin and bone. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2014, 307, R970-R977.	1.8	27
47	A new titanium biofunctionalized interface based on poly(pyrrole-3-acetic acid) coating: proliferation of osteoblast-like cells and future perspectives. Journal of Materials Science: Materials in Medicine, 2007, 18, 1781-1789.	3.6	26
48	Effects of Sweet Cherry Polyphenols on Enhanced Osteoclastogenesis Associated With Childhood Obesity. Frontiers in Immunology, 2019, 10, 1001.	4.8	24
49	The effect of Irisin on bone cells <i>in vivo</i> and <i>in vitro</i> . Biochemical Society Transactions, 2021, 49, 477-484.	3.4	24
50	Skeleton and Glucose Metabolism: A Bone-Pancreas Loop. International Journal of Endocrinology, 2015, 2015, 1-7.	1.5	23
51	Irisin Serum Levels in Metabolic Syndrome Patients Treated with Three Different Diets: A Post-Hoc Analysis from a Randomized Controlled Clinical Trial. Nutrients, 2018, 10, 844.	4.1	23
52	Systemic Administration of Recombinant Irisin Accelerates Fracture Healing in Mice. International Journal of Molecular Sciences, 2021, 22, 10863.	4.1	22
53	Irisin and Secondary Osteoporosis in Humans. International Journal of Molecular Sciences, 2022, 23, 690.	4.1	21
54	Accumulation of homocysteine by decreasing concentrations of folate, vitamin B12 and B6 does not influence the activity of human osteoblasts in vitro. Clinica Chimica Acta, 2007, 384, 129-134.	1.1	20

#	ARTICLE	IF	CITATIONS
55	Sclerostin stimulates angiogenesis in human endothelial cells. <i>Bone</i> , 2017, 101, 26-36.	2.9	20
56	LIGHT/TNFSF14 as a New Biomarker of Bone Disease in Multiple Myeloma Patients Experiencing Therapeutic Regimens. <i>Frontiers in Immunology</i> , 2018, 9, 2459.	4.8	20
57	Irisin promotes growth, migration and matrix formation in human periodontal ligament cells. <i>Archives of Oral Biology</i> , 2020, 111, 104635.	1.8	20
58	The Myokine Irisin Promotes Osteogenic Differentiation of Dental Bud-Derived MSCs. <i>Biology</i> , 2021, 10, 295.	2.8	20
59	The "Love Hormone" Oxytocin Regulates the Loss and Gain of the Fat-Bone Relationship. <i>Frontiers in Endocrinology</i> , 2015, 6, 79.	3.5	18
60	Deletion of the Transcription Factor PGC1 $\beta$ in Mice Negatively Regulates Bone Mass. <i>Calcified Tissue International</i> , 2018, 103, 638-652.	3.1	17
61	Impairment of Bone Remodeling in <i>LIGHT/TNFSF14</i> -Deficient Mice. <i>Journal of Bone and Mineral Research</i> , 2018, 33, 704-719.	2.8	16
62	LIGHT/TNFSF14 regulates estrogen deficiency-induced bone loss. <i>Journal of Pathology</i> , 2020, 250, 440-451.	4.5	15
63	The Role of OPG/TRAIL Complex in Multiple Myeloma: The OPG/TRAIL Complex in an In Vitro Osteoclastogenesis Model Derived From Human Multiple Myeloma-Bone Disease. <i>Annals of the New York Academy of Sciences</i> , 2006, 1068, 334-340.	3.8	14
64	The formation of osteoclasts in multiple myeloma bone disease patients involves the secretion of soluble decoy receptor 3. <i>Annals of the New York Academy of Sciences</i> , 2010, 1192, 298-302.	3.8	14
65	Suppressive effects of tenofovir disoproxil fumarate, an antiretroviral prodrug, on mineralization and type II and type III sodium-dependent phosphate transporters expression in primary human osteoblasts. <i>Journal of Cellular Biochemistry</i> , 2018, 119, 4855-4866.	2.6	13
66	High expression of TRAIL by osteoblastic differentiated dental pulp stem cells affects myeloma cell viability. <i>Oncology Reports</i> , 2018, 39, 2031-2039.	2.6	13
67	The Novel Role of PGC1 $\beta$ in Bone Metabolism. <i>International Journal of Molecular Sciences</i> , 2021, 22, 4670.	4.1	12
68	Antidepressant Effect of Intermittent Long-Term Systemic Administration of Irisin in Mice. <i>International Journal of Molecular Sciences</i> , 2022, 23, 7596.	4.1	11
69	Synovial Fluid Fibroblasts and Lymphocytes Support the Osteoclastogenesis in Human Psoriatic Arthritis. <i>Annals of the New York Academy of Sciences</i> , 2007, 1117, 159-164.	3.8	10
70	Irisin Serum Levels and Skeletal Muscle Assessment in a Cohort of Charcot-Marie-Tooth Patients. <i>Frontiers in Endocrinology</i> , 2022, 13, .	3.5	10
71	Human Myeloma Cell Lines Induce Osteoblast Downregulation of CD99 Which Is Involved in Osteoblast Formation and Activity. <i>Journal of Immunology Research</i> , 2015, 2015, 1-13.	2.2	6
72	Osteotropic Cancers: From Primary Tumor to Bone. <i>Clinical Reviews in Bone and Mineral Metabolism</i> , 2013, 11, 94-102.	0.8	5

#	ARTICLE	IF	CITATIONS
73	Adrenergic stimulation decreases osteoblast oxytocin synthesis. <i>Annals of the New York Academy of Sciences</i> , 2011, 1237, 53-57.	3.8	4
74	Treatment of osteoporosis in children with glucocorticoid-treated diseases. <i>Expert Review of Endocrinology and Metabolism</i> , 2014, 9, 525-534.	2.4	4
75	<i>Bone Cells.</i> , 2014, , 3-13.		3
76	Myokineâ€”Irisinâ€”and Its Effects Linking Bone and Muscle Function. <i>Clinical Reviews in Bone and Mineral Metabolism</i> , 2018, 16, 16-21.	0.8	3
77	In Reply to the Letter to the Editor: Involvement of Irisin in Age-Related Osteoporosis and Its Inhibitory Effect on the Senescent Marker p21 in Osteoblasts. <i>Journal of Bone and Mineral Research</i> , 2020, 36, 1420-1421.	2.8	3
78	<i>Anatomy and Physiology of Skeletal Tissue: The Bone Cells.</i> , 2018, , 1-23.		2
79	The effects of bone pÃ¢tÃ© on human osteoblasts cell cultures. <i>European Archives of Oto-Rhino-Laryngology</i> , 2016, 273, 1399-1404.	1.6	1
80	Mechanisms of Altered Bone Remodeling in Multiple Myeloma. <i>Clinical Reviews in Bone and Mineral Metabolism</i> , 2017, 15, 151-161.	0.8	1
81	<i>Ovarian Hormones and Bone.</i> , 2020, , 583-587.		0
82	<i>Muscle-Derived Soluble Mediators Regulating Bone.</i> , 2020, , 356-361.		0
83	<i>Posterior Pituitary Hormones and Bone.</i> , 2020, , 519-526.		0
84	<i>Pituitary Hormones and the Pathophysiology of Osteoporosis.</i> , 2012, , 87-100.		0
85	The Role of LIGHT in Multiple Myeloma-Bone Disease. <i>Blood</i> , 2014, 124, 3362-3362.	1.4	0
86	Evaluation of serum concentration of Irisin and molecules affecting the musculoskeletal system after 10-day Bed Rest. <i>Bone Reports</i> , 2022, 16, 101546.	0.4	0
87	Irisin is a potential biomarker to predict muscular atrophy and bone loss progression in Charcot-Marie-Tooth Patients. <i>Bone Reports</i> , 2022, 16, 101564.	0.4	0